{
    "clinical_study": {
        "@rank": "31792", 
        "arm_group": {
            "arm_group_label": "High-dose IL-2", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Partially HLA-matched irradiated donor lymphcyte infusion alone resulted in 27% overall\n      response rate (ORR) in advanced renal cell carcinoma without significant toxicities. In\n      addition, high-dose interleukin-2 (IL-2)showed an ORR of 6-21% in metastatic melanoma or\n      renal cell carcinoma with a durable response in patients who achieved complete remission.\n      Therefore, irradiated donor lymphocyte infusion plus high-dose IL-2 might show a synergistic\n      anti-tumor activity agaist relapsed or metastatic melanoma or renal cell carcinoma."
        }, 
        "brief_title": "Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Malignant Melanoma and Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell", 
                "Melanoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed malignant melanoma or renal cell carcinoma\n\n          -  At stage IV or relapse\n\n          -  At least one prior chemotherapy including targeted agents\n\n          -  At least one haploidential or partially matched-HLA donor\n\n          -  ECOG performance status 0-1\n\n          -  Age 18-75 years\n\n          -  Measurable lesion\n\n          -  Adequate bone marrow, liver, and renal functions\n\n        Exclusion Criteria:\n\n          -  Chemotherapy within 4 weeks\n\n          -  Stem cell transplantation\n\n          -  Active CNS metastasis\n\n          -  Hypersensitivity to IL-2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925118", 
            "org_study_id": "H-1305-6130491"
        }, 
        "intervention": {
            "arm_group_label": "High-dose IL-2", 
            "intervention_name": "Irradiated donor lymphocyte infusion", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "contact": {
                "email": "heo1013@snu.ac.kr", 
                "last_name": "Dae Seog Heo, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "investigator": {
                "last_name": "Dae Seog Heo, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Irradiated Donor Lymphocyte Infusion Plus High-dose Interleukin-2 in Patients With Metastatic Malignant Melanoma and Renal Cell Carcinoma", 
        "overall_contact": {
            "email": "heo1013@snu.ac.kr", 
            "last_name": "Dae Seog Heo, MD, PhD"
        }, 
        "overall_contact_backup": {
            "email": "gabriel9@snu.ac.kr", 
            "last_name": "Tae Min Kim, MD, PhD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "12-week modified immune-related response rate", 
            "safety_issue": "No", 
            "time_frame": "12-week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925118"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Dae Seog Heo", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "6-week modified immune-related response rate", 
                "safety_issue": "No", 
                "time_frame": "6-week"
            }, 
            {
                "measure": "Overall response rate based on RECIST v1.1", 
                "safety_issue": "No", 
                "time_frame": "6/12-week"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "6-month"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "1-year"
            }, 
            {
                "measure": "Immune-related adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12-week"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}